SocialPicks Sentiment:
** v.s.
other stocks
|
This Quarter's Sentiment:
|
|
|
DNDN Analysis & Videos »
DNDN: Bull or Bear?
Healthcare Conference Update: A New Strategy for ImmunoCellular (OTC: IMUC.OB)
DNDN
|
|
|
+24.48%
in
64 days
I had the opportunity last week to discuss the updated strategy and expected milestones for ImmunoCellular Therapeutics (OTC: IMUC.OB) in 2010 and beyond with CEO, Manish Singh, following the conclusion of the OneMed, JP Morgan, and other healthcare conferences in San Francisco. IMUC is an emerging cancer immunotherapy company that is developing therapeutic and diagnostic product candidates taking aim at the root cause of the disease, cancer stem cells, based on two technology platforms that include active (therapeutic cancer vaccines) and passive (monoclonal antibodies) approaches. <> <o:...
|
QI / Mentor Capital Updates: New Video, Upcoming Presentation, Financials
DNDN
|
|
|
+10.54%
in
15 days
(closed on 01/17/10)
<> The <font> ProActive News Room website for Quantum Immunologics </font> (QI) has been updated to include a new video interview, a 25-page PDF update report, and a link for more information on QI’s upcoming presentation at the OneMed Forum in San Francisco on 13-January. In addition, the News Room site contains a three-minute video animation for an overview of the science behind QI’s experimental OFA-based cancer vaccine and a 22-page report for Mentor Capital (OTC: MNTR.PK), which is a public-traded private equity firm that has an agreement to purchase at least a 20% stake (187,000 s<><><><><><><><><><><><><><><><><><><><><>...
|
Pending Provenge approval by FDA
DNDN
|
|
|
+9.24%
in
7 days
(closed on 01/06/10)
DNDN has a PUFDA date of 05/01/2010 for Provenge. There is a good probability that this time FDA would approve Porvenge which should be a catalist for DNDN stock to move higher. After approval DNDN should be in a good position to partner with big pharma which should keep the stock moving even higher. stocktawk
|
Mentor Capital Plans Early ’10 Launch of Cancer Vaccine Active Index Fund
DNDN
|
|
|
+1.08%
in
12 days
(closed on 01/02/10)
Last week, Mentor Capital (OTC: MNTR.PK) announced plans to launch an actively managed Cancer Immunotherapy (CI) Index fund shortly after New Year’s Day that will be based on the underlying <font> Mentor Capital CI Index </font> , which has gained 45% on an equal-weight basis since its inception on 7/10/09. MNTR.PK intends to invest a significant portion of the cash proceeds from the exercise of warrants which are currently outstanding on a stepped-price basis at $1, $3, $5, and $7 per share. <> The Company also announced that $1.2 million each in initial seed funding for...
|
Cancer Vaccines: Investing Opportunities beyond Dendreon (NASDAQ: DNDN)
DNDN
|
|
|
-4.55%
in
23 days
(closed on 12/21/09)
 Despite the setbacks and pitfalls experienced by early-stage pioneers in the cancer immunotherapy / therapeutic cancer vaccine space such as Cell Genesys, Favrille, and Genitope; recent advancements and study results are encouraging while Dendreon (NASDAQ: DNDN) awaits a FDA decision that is expected by May 2010 for its prostate cancer vaccine, Provenge, which is poised to become the first active cellular immunotherapy approved by the Agency to harness a patient's own immune system in the fight against the disease. <> Last week, a group of Harvard bioengineers and im...
|
BioMed News Bytes: CombinatoRx, Dendreon, Photocure, Pozen
DNDN
|
|
|
-2.51%
in
8 days
(closed on 11/28/09)
On 11/2/09, Dendreon (NASDAQ: DNDN) announced that it has completed the submission of its amended Biologics License Application (BLA) for PROVENGE (sipuleucel-T), seeking approval for men with metastatic castrate-resistant prostate cancer (CRPC). The amended BLA includes data from the IMPACT trial, which was conducted under a Special Protocol Assessment agreement with the FDA. The IMPACT study met its pre-specified primary endpoint demonstrating a statistically significant improvement in overall survival in men with metastatic CRPC. <> PROVENGE is currently available through several ong...
|
New Global Equity Index to Track Immunotherapy, Vaccine Stocks
DNDN
|
|
|
+5.55%
in
16 days
(closed on 11/20/09)
Earlier this week, Dendreon (NASDAQ: DNDN ) announced that it has completed the submission of its amended Biologics License Application ( BLA ) for PROVENGE (sipuleucel-T), seeking approval for men with metastatic castrate-resistant prostate cancer ( CRPC ). The amended BLA includes data from the IMPACT trial, which was conducted under a Special Protocol Assessment agreement with the FDA. The IMPACT study met its pre-specified primary endpoint demonstrating a statistically significant improvement in overall survival in men with metastatic CRPC. <> PROVENGE is currently ava...
|
New Stock Indexes to Track Trends in Healthcare Sector
DNDN
|
|
|
-0.86%
in
7 days
(closed on 11/04/09)
Coming Soon. . . a premium service offered in collaboration with Investars YOU for full access to a global database of over 1,000 stocks which are organized and managed within my 20 ProActive HavRx stock indexes . The expected pricing for premium access is $60 per year and will include full access to all of the component stocks in the indexes and tracking data for the indexes. <> Emerging Cancer Diagnostic / Therapeutic (Dx / Tx) Index
The actively managed HavRx Emerging Cancer Dx / Tx Index constituents reflect a cross-section of emerging cancer companies with <><><><><><><><><><><><><><><><><><><>< />< /><><>< />< /><><>< />< />< />< /><><>< />< /><><>< />< /><><>< />< /><><><><><><><><><><>< />< /><><>< />< />< />< /><><>< />< /><><>< />< /><><>< />< />< />< /><><>< />< />< />< /><><>< />< />< />< /><><>< />< /><><><><><><><><><>...
|
Quantum Immunologics: Developing Universal Therapeutic Cancer Vaccine
DNDN
|
|
|
-3.58%
in
3 days
(closed on 10/28/09)
<> <> Quantum Immunologics (QI) (privately held) is dedicated to improving the treatment outcome and quality of life for cancer patients through the research, development, and production of innovative therapeutic and diagnostic products that are based on the universal cancer antigen (oncofetal antigen or OFA). Quantum’s integrated approach to the treatment, diagnosis, and monitoring of cancer is being developed to create novel, individualized products and services that offer a greatly reduced cost, a high rate of efficacy, and minimal side effects compared to conventional treatments such as ra<><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><>...
|
ImmunoCellular (OTC: IMUC.OB): Top Gainer in Cancer Immunotherapy Index
DNDN
|
|
|
+4.25%
in
39 days
(closed on 10/25/09)
<> The Mentor Capital Cancer Immunotherapy (CI) Index of 10 leading cancer immunotherapy stocks has increased 58% in its first two months of reporting. The CI Index gain was paced by the 233% share price improvement of ImmunoCellular Theraputics, Inc. (OTC: IMUC.OB) under the leadership of CEO Manish Singh, PhD. The increased interest in the immunotherapy companies and growth of the sector followed the positive Phase 3 results of Dendreon (NASDAQ: DNDN), a CI Index component company, for its prostate cancer product Provenge and resulting 1,000% share price improvement during the Spring of 200...
|
Quantum Immunologics: Rodman Conference Recap
DNDN
|
|
|
-0.38%
in
23 hours
(closed on 09/16/09)
<> In addition, <> <> <font> QI’s cancer immunotherapy<><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><>...
|
Mentor Capital (MNTR.PK) Top Gainer in Cancer Immunotherapy Index
DNDN
|
|
|
+0.30%
in
8 hours
(closed on 08/29/09)
SAN DIEGO--(BUSINESS WIRE)--The Cancer Immunotherapy Index of ten leading cancer immunotherapy stocks increased 23% since its inception July 10, 2009. The CI Index was developed by Mentor Capital as a peer group index against which investors could bench mark stock performance in the rapidly growing immunotherapy sector. In this first reporting, the strong six-week CI Index gain was paced by the 78% share price improvement of Mentor Capital, Inc. (Pink Sheets: MNTR - News ). <> <> <> On July 10, 2009, Mentor Capital announced it had acquired a significant interest in an...
|
Mentor Capital (MNTR.PK): A Stealth Cancer Immunotherapy Play
DNDN
|
|
|
-1.70%
in
2 days
(closed on 08/28/09)
<> On 7/8/09 , in the first of four steps leading to an anticipated merger and name change, Mentor Capital (MNTR.PK) acquired a 20% ownership stake in an innovative clinical stage cancer immunotherapy company, <font> Quantum Immunologics, Inc. </font> (QI). QI is a privately held company with a goal of initially marketing its active immunotherapy for the treatment of breast cancer in the U.S. <> , in addition to planning for new studies in other types of cancer and a new cancer screening tool. Mentor Capital is providing funding for QI to complete its ongoing, FDA-authorize...
|
New Indexes to Track Healthcare Trends and More
DNDN
|
|
|
-1.59%
in
22 days
(closed on 08/26/09)
Below are links and descriptions for 23 new stock indexes I have created, revised, and tracked over the past few years which are now featured at a new website called Investars YOU. The new site includes automated index tracking, allows investors to create custom stock portfolios based on their individual preferences, and now features free access to all of the component stocks in each of my indexes. Some of the top performing stocks from my healthcare indexes on a year-to-date basis are highlighted below.
Cosmetic & Restorative Medicine Index: Allergan (NYSE:AGN) (+38%) <> The <> ...
|
People Bullish on DNDN
People Bearish on DNDN
|
ROCK-STAR INVESTORS
|
|
POPULAR STOCKS
|
|
TODAY'S HEADLINES
|
|
TODAY'S TOP PICKS
|
|
|
| StreetInsider.com on DNDN |
|
|
|
|
tanumoy
(-29.95% risk: conservative)
|
|
|
More Resources
|
About Dendreon Corp
- Answers.com
